How Will the Market React to Zomedica Corp (ZOM) Stock Getting a Bearish Rating

Overall market sentiment has been down on Zomedica Corp (ZOM) stock lately. ZOM receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Zomedica Corp has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ZOM!

See Full ZOM Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ZOM Stock Today?

Zomedica Corp (ZOM) stock is trading at $0.31 as of 1:34 PM on Wednesday, Apr 6, a drop of -$0.01, or -4.35% from the previous closing price of $0.33. The stock has traded between $0.31 and $0.33 so far today. Volume today is below average. So far 6,675,162 shares have traded compared to average volume of 16,781,131 shares. To see InvestorsObserver's Sentiment Score for Zomedica Corp click here.

More About Zomedica Corp

Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is currently focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments: Diagnostic & Therapeutics. It earns the majority of revenue from the therapeutics segment. Click Here to get the full Stock Report for Zomedica Corp stock.